CT与MRI辅助的荧光断层重建用于生物分布分析
研究建立全身CT-MRI-荧光断层(FLT)三模态成像方法并与CT-FLT比较,通过体模、死亡小鼠荧光插入物及活体SKH1小鼠AF750标记免疫球蛋白生物分布分析验证。MRI软组织对比使肝、肾、脑等器官分割更可靠,虽未显著改变FLT定量,但能更好归属荧光信号并显示胆囊、甲状腺和脑,从而显著改善药代动力学分析。
要点
- CT-MRI-FLT三模态成像可行,MRI软组织对比使肝、脾、肾分割较CT更可靠。
- MRI-FLT可额外显示胆囊、甲状腺和脑,利于荧光信号归属和药代分析。
- 与CT-FLT相比,加入MRI信息未显著改变FLT重建和定量结果。
核心结论
- 全身CT-MRI-FLT作为一种新型三模态成像方法得以实现,能更准确归属荧光信号,从而显著改善药代动力学分析。
研究设计与样本
- 研究先扫描充水和椰子油的体模,再定量死亡小鼠中插入物的Cy7浓度,最后分析活体SKH1小鼠中AF750标记免疫球蛋白(IgG、IgA)的生物分布。
- MRI采用脂肪-水分离mDixon序列,CT、MRI与FLT通过小鼠固定架内充填白色凡士林的标记物进行配准。
关键影像表现/征象
- 体模分割在校正梯度线性失真和化学位移后显示良好一致性,死亡和活体小鼠器官分割显示融合充分一致。
- CT-FLT重建仅考虑软组织、皮肤、肺、脂肪和骨散射的一般值,MRI软组织对比使额外考虑肝、肾和脑成为可能。
- MRI额外实现胆囊、甲状腺和脑的可视化,肝、脾、肾分割因轮廓更清晰而较CT更可靠。
诊断标准与关键数值
- CT-MRI融合通过Dice评分比较分割一致性确认,体模分割显示良好一致性。
- 死亡小鼠中60 pmol荧光插入物在不同位置时,CT、MRI或CT-MRI支持的FLT重建结果相当。
临床应用与阅片要点
- MRI-FLT因器官分割更可靠,能更好归属荧光信号并得出更具区分度的结论。
- 扩展散射图时,准确分割器官和整个小鼠身体很重要。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Optical fluorescence imaging can track the biodistribution of fluorophore-labeled drugs, nanoparticles, and antibodies longitudinally. In hybrid computed tomography-fluorescence tomography (CT-FLT), CT provides the anatomical information to generate scattering and absorption maps supporting a 3-dimensional reconstruction from the raw optical data. However, given the CT's limited soft tissue contrast, fluorescence reconstruction and quantification can be inaccurate and not sufficiently detailed. Magnetic resonance imaging (MRI) can overcome these limitations and extend the options for tissue characterization. Thus, we aimed to establish a hybrid CT-MRI-FLT approach for whole-body imaging and compared it with CT-FLT.
MATERIALS AND METHODS: The MRI-based hybrid imaging approaches were established first by scanning a water and coconut oil-filled phantom, second by quantifying Cy7 concentrations of inserts in dead mice, and finally by analyzing the biodistribution of AF750-labeled immunoglobulins (IgG, IgA) in living SKH1 mice. Magnetic resonance imaging, acquired with a fat-water-separated mDixon sequence, CT, and FLT were co-registered using markers in the mouse holder frame filled with white petrolatum, which was solid, stable, and visible in both modalities.
RESULTS: Computed tomography-MRI fusion was confirmed by comparing the segmentation agreement using Dice scores. Phantom segmentations showed good agreement, after correction for gradient linearity distortion and chemical shift. Organ segmentations in dead and living mice revealed adequate agreement for fusion. Marking the mouse holder frame and the successful CT-MRI fusion enabled MRI-FLT as well as CT-MRI-FLT reconstructions. Fluorescence tomography reconstructions supported by CT, MRI, or CT-MRI were comparable in dead mice with 60 pmol fluorescence inserts at different locations. Although standard CT-FLT reconstruction only considered general values for soft tissue, skin, lung, fat, and bone scattering, MRI's more versatile soft tissue contrast enabled the additional consideration of liver, kidneys, and brain. However, this did not change FLT reconstructions and quantifications significantly, whereas for extending scattering maps, it was important to accurately segment the organs and the entire mouse body. The various FLT reconstructions also provided comparable results for the in vivo biodistribution analyses with fluorescent immunoglobulins. However, MRI additionally enabled the visualization of gallbladder, thyroid, and brain. Furthermore, segmentations of liver, spleen, and kidney were more reliable due to better-defined contours than in CT. Therefore, the improved segmentations enabled better assignment of fluorescence signals and more differentiated conclusions with MRI-FLT.
CONCLUSIONS: Whole-body CT-MRI-FLT was implemented as a novel trimodal imaging approach, which allowed to more accurately assign fluorescence signals, thereby significantly improving pharmacokinetic analyses.
引用
- Schraven S, Brück R, Rosenhain S, et al. CT- and MRI-Aided Fluorescence Tomography Reconstructions for Biodistribution Analysis. Invest Radiol. 2023. PMID: 38038691. doi:10.1097/RLI.0000000000001052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。